Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 1/2010

01-01-2010 | Article

The endothelin receptor antagonist avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein E knockout mice

Authors: A. M. D. Watson, J. Li, C. Schumacher, M. de Gasparo, B. Feng, M. C. Thomas, T. J. Allen, M. E. Cooper, K. A. M. Jandeleit-Dahm

Published in: Diabetologia | Issue 1/2010

Login to get access

Abstract

Aims/hypothesis

There is convincing evidence that the endothelin system contributes to diabetic nephropathy and cardiovascular disease. This study aimed to assess the effects of the non-peptidergic endothelin receptor A (ETA) antagonist avosentan in a mouse model of accelerated diabetic nephropathy and atherosclerosis in comparison with the ACE inhibitor, quinapril.

Methods

Apolipoprotein E (Apoe) knockout (KO) mice (n = 20 per group, five groups) were randomised to the following groups: non-diabetic controls and streptozotocin-induced diabetic animals gavaged daily for 20 weeks with placebo, avosentan (high dose: 30 mg/kg, or low dose: 10 mg/kg) or quinapril (given in drinking water, 30 mg/kg).

Results

BP was unchanged by avosentan treatment but decreased with quinapril treatment. Diabetes-associated albuminuria was significantly attenuated by high-dose avosentan after 10 and 20 weeks of treatment. Diabetic animals showed a decreased creatinine clearance, which was normalised by avosentan treatment. In diabetic mice, high-dose avosentan treatment significantly attenuated the glomerulosclerosis index, mesangial matrix accumulation, glomerular accumulation of the matrix proteins collagen IV, and renal expression of genes encoding connective tissue growth factor, vascular endothelial growth factor, transforming growth factor β and nuclear factor κB (p65 subunit). Furthermore, high-dose avosentan treatment was also associated with reduced expression of the genes for ETA, ETB and angiotensin receptor 1. The renoprotective effects of avosentan were comparable or superior to those observed with quinapril. High-dose avosentan also significantly attenuated diabetes-associated aortic atherosclerosis in Apoe KO mice and reduced macrophage infiltration and aortic nitrotyrosine expression.

Conclusions/interpretation

This study demonstrates that ETA blockade with avosentan may provide an alternate therapeutic strategy for the treatment of diabetic micro- and macrovascular complications.
Appendix
Available only for authorised users
Literature
1.
Neuhofer W, Pittrow D (2006) Role of endothelin and endothelin receptor antagonists in renal disease. Eur J Clin Invest 36(Suppl 3):78–88CrossRefPubMed
2.
Hocher B, Thone-Reineke C, Rohmeiss P et al (1997) Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension. J Clin Invest 99:1380–1389CrossRefPubMed
3.
Warram JH, Scott LJ, Hanna LS et al (2000) Progression of microalbuminuria to proteinuria in type 1 diabetes: nonlinear relationship with hyperglycemia. Diabetes 49:94–100CrossRefPubMed
4.
Nakamura T, Ebihara I, Fukui M, Tomino Y, Koide H (1995) Effect of a specific endothelin receptor A antagonist on mRNA levels for extracellular matrix components and growth factors in diabetic glomeruli. Diabetes 44:895–899CrossRefPubMed
5.
Hocher B, Schwarz A, Reinbacher D et al (2001) Effects of endothelin receptor antagonists on the progression of diabetic nephropathy. Nephron 87:161–169CrossRefPubMed
6.
Dhein S, Hochreuther S, Aus Dem Spring C, Bollig K, Hufnagel C, Raschack M (2000) Long-term effects of the endothelin(A) receptor antagonist LU 135252 and the angiotensin-converting enzyme inhibitor trandolapril on diabetic angiopathy and nephropathy in a chronic type I diabetes mellitus rat model. J Pharmacol Exp Ther 293:351–359PubMed
7.
Chen S, Evans T, Deng D, Cukiernik M, Chakrabarti S (2002) Hyperhexosemia induced functional and structural changes in the kidneys: role of endothelins. Nephron 90:86–94CrossRefPubMed
8.
Forbes JM, Hewitson TD, Becker GJ, Jones CL (2001) Simultaneous blockade of endothelin A and B receptors in ischemic acute renal failure is detrimental to long-term kidney function. Kidney Int 59:1333–1341CrossRefPubMed
9.
Dieterle W, Mann J, Kutz K (2004) Pharmacokinetics and pharmacodynamics of the ETA-selective endothelin receptor antagonist SPP301 in healthy human subjects. J Clin Pharmacol 44:59–66CrossRefPubMed
10.
Wenzel RR, Littke T, Kuranoff S et al (2009) Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J Am Soc Nephrol 20:655–664CrossRefPubMed
11.
Lassila M, Seah KK, Allen TJ et al (2004) Accelerated nephropathy in diabetic apolipoprotein E-knockout mouse: role of advanced glycation end products. J Am Soc Nephrol 15:2125–2138CrossRefPubMed
12.
Tse J, Martin-McNaulty B, Halks-Miller M et al (1999) Accelerated atherosclerosis and premature calcified cartilaginous metaplasia in the aorta of diabetic male Apo E knockout mice can be prevented by chronic treatment with 17 beta-estradiol. Atherosclerosis 144:303–313CrossRefPubMed
13.
Battistini B, Berthiaume N, Kelland NF, Webb DJ, Kohan DE (2006) Profile of past and current clinical trials involving endothelin receptor antagonists: the NOVEL ‘Sentan’ class of drug. Exp Biol Med (Maywood) 231:653–695
14.
Krege JH, Hodgin JB, Hagaman JR, Smithies O (1995) A noninvasive computerized tail–cuff system for measuring blood pressure in mice. Hypertension 25:1111–1115PubMed
15.
Candido R, Jandeleit-Dahm KA, Cao Z et al (2002) Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice. Circulation 106:246–253CrossRefPubMed
16.
Candido R, Allen TJ, Lassila M et al (2004) Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis. Circulation 109:1536–1542CrossRefPubMed
17.
Soro-Paavonen A, Watson AMD, Li J, et al (2008) Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes 57:2461–2469CrossRefPubMed
18.
Jandeleit-Dahm K, Allen TJ, Youssef S, Gilbert RE, Cooper ME (2000) Is there a role for endothelin antagonists in diabetic renal disease? Diabetes Obes Metab 2:15–24CrossRefPubMed
19.
Khan MA, Dashwood MR, Mumtaz FH, Thompson CS, Mikhailidis DP, Morgan RJ (1999) Upregulation of endothelin A receptor sites in the rabbit diabetic kidney: potential relevance to the early pathogenesis of diabetic nephropathy. Nephron 83:261–267CrossRefPubMed
20.
King AJ, Brenner BM, Anderson S (1989) Endothelin: a potent renal and systemic vasoconstrictor peptide. Am J Physiol Renal Physiol 256:F1051–F1058
21.
Calkin AC, Giunti S, Jandeleit-Dahm KA, Allen TJ, Cooper ME, Thomas MC (2006) PPAR-alpha and -gamma agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse. Nephrol Dial Transplant 21:2399–2405CrossRefPubMed
22.
Gomez-Garre D, Largo R, Tejera N, Fortes J, Manzarbeitia F, Egido J (2001) Activation of NF-kappaB in tubular epithelial cells of rats with intense proteinuria: role of angiotensin II and endothelin-1. Hypertension 37:1171–1178PubMed
23.
Jandeleit-Dahm K, Lassila M, Davis BJ et al (2005) Anti-atherosclerotic and renoprotective effects of combined angiotensin-converting enzyme and neutral endopeptidase inhibition in diabetic apolipoprotein E-knockout mice. J Hypertens 23:2071–2082CrossRefPubMed
24.
Steffes MW, Bilous RW, Sutherland DER, Mauer SM (1992) Cell and matrix components of the glomerular mesangium in type I diabetes. Diabetes 41:679–684CrossRefPubMed
25.
Cooper ME, Allen TJ, Macmillan PA, Clarke BE, Jerums G, Doyle AE (1989) Enalapril retards glomerular basement membrane thickening and albuminuria in the diabetic rat. Diabetologia 32:326–328CrossRefPubMed
26.
Mauer M, Zinman B, Gardiner R et al (2009) Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 361:40–51CrossRefPubMed
27.
Rizkalla B, Forbes JM, Cao Z, Boner G, Cooper ME (2005) Temporal renal expression of angiogenic growth factors and their receptors in experimental diabetes: role of the renin–angiotensin system. J Hypertens 23:153–164CrossRefPubMed
28.
Lassila M, Jandeleit-Dahm K, Seah KK et al (2005) Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice. J Am Soc Nephrol 16:363–373CrossRefPubMed
29.
Susztak K, Bottinger E, Novetsky A et al (2004) Molecular profiling of diabetic mouse kidney reveals novel genes linked to glomerular disease. Diabetes 53:784–794CrossRefPubMed
30.
Yamaguchi H, Igarashi M, Hirata A et al (2004) Progression of diabetic nephropathy enhances the plasma osteopontin level in type 2 diabetic patients. Endocr J 51:499–504CrossRefPubMed
31.
Bruemmer D, Collins AR, Noh G et al (2003) Angiotensin II-accelerated atherosclerosis and aneurysm formation is attenuated in osteopontin-deficient mice. J Clin Invest 112:1318–1331PubMed
32.
Lorenzen J, Shah R, Biser A et al (2008) The role of osteopontin in the development of albuminuria. J Am Soc Nephrol 19:884–890CrossRefPubMed
33.
Sorokin A, Kohan DE (2003) Physiology and pathology of endothelin-1 in renal mesangium. Am J Physiol Renal Physiol 285:F579–F589PubMed
34.
Gomez-Garre D, Ruiz-Ortega M, Ortego M et al (1996) Effects and interactions of endothelin-1 and angiotensin II on matrix protein expression and synthesis and mesangial cell growth. Hypertension 27:885–892PubMed
35.
Orth SR, Viedt C, Amann K, Ritz E (2001) Endothelin in renal diseases and cardiovascular remodeling in renal failure. Intern Med 40:285–291CrossRefPubMed
36.
Leehey DJ, Singh AK, Alavi N, Singh R (2000) Role of angiotensin II in diabetic nephropathy. Kidney Int Suppl 77:S93–S98CrossRefPubMed
37.
Goddard J, Johnston NR, Hand MF et al (2004) Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: a comparison of selective and combined endothelin receptor blockade. Circulation 109:1186–1193CrossRefPubMed
38.
Spratt JC, Goddard J, Patel N, Strachan FE, Rankin AJ, Webb DJ (2001) Systemic ETA receptor antagonism with BQ-123 blocks ET-1 induced forearm vasoconstriction and decreases peripheral vascular resistance in healthy men. Br J Pharmacol 134:648–654CrossRefPubMed
39.
Sasser JM, Sullivan JC, Hobbs JL et al (2007) Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism. J Am Soc Nephrol 18:143–154CrossRefPubMed
40.
Barton M, Haudenschild CC, d’Uscio LV, Shaw S, Munter K, Luscher TF (1998) Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A 95:14367–14372CrossRefPubMed
41.
Orth SR, Odoni G, Amann K, Strzelczyk P, Raschack M, Ritz E (1999) The ET(A) receptor blocker LU 135252 prevents chronic transplant nephropathy in the ‘Fisher to Lewis’ model. J Am Soc Nephrol 10:387–391PubMed
42.
Fukuda G, Khan ZA, Barbin YP, Farhangkhoee H, Tilton RG, Chakrabarti S (2005) Endothelin-mediated remodeling in aortas of diabetic rats. Diabetes Metab Res Rev 21:367–375CrossRefPubMed
43.
Nakashima Y, Plump AS, Raines EW, Breslow JL, Ross R (1994) ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb 14:133–140PubMed
44.
Jandeleit-Dahm K, Watson A, Soro-Paavonen A et al (2008) The novel endothelin receptor A (ET-A) antagonist SPP 301 attenuates albuminuria and renal structural injury in streptozotocin-induced diabetic ApoE knockout mice. J Hypertens 26:S194 abstract
Metadata
Title
The endothelin receptor antagonist avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein E knockout mice
Authors
A. M. D. Watson
J. Li
C. Schumacher
M. de Gasparo
B. Feng
M. C. Thomas
T. J. Allen
M. E. Cooper
K. A. M. Jandeleit-Dahm
Publication date
01-01-2010
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 1/2010
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-009-1540-3

Other articles of this Issue 1/2010

Diabetologia 1/2010 Go to the issue

Article

Single pancreatic beta cells co-express multiple islet hormone genes in mice

Article

Regulation of wingless-type MMTV integration site family (WNT) signalling in pancreatic islets from wild-type and obese mice

Letter

Using individual patient data in meta-analyses of glucose-lowering studies

Letter

Intensive glucose control and macrovascular outcomes in type 2 diabetes. Reply to Emanuele NV [letter] and Yudkin JS, Richter B [letter]

Article

Cell division autoantigen 1 plays a profibrotic role by modulating downstream signalling of TGF-β in a murine diabetic model of atherosclerosis

Letter

Diabetes treatment with insulin glargine and risk of malignancy: methodological pitfalls and ethical issues
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits